An eye drug biotech banks $118M and stocks its executive suite
Source ↗
👁 0
💬 0
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.
Comments (0)